Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease

Brain

Volumn 138, Issue 10, 2015, Pages 3089-3099

  Frings, Lars ^a   Hellwig, Sabine ^a   Spehl, Timo S ^a   Bormann, Tobias ^a   Buchert, Ralph ^b   Vach, Werner ^a   Minkova, Lora ^a   Heimbach, Bernhard ^a   Klöppel, Stefan ^a   Meyer, Philipp T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alzheimer's disease; amyloid; biomarkers; hemispheric differences; positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN REGION; COGNITION; COGNITIVE DEFECT; DATA BASE; DEPTH PERCEPTION; DISEASE SEVERITY; FEMALE; HEMISPHERIC DOMINANCE; HUMAN; LANGUAGE DELAY; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MIDDLE FRONTAL GYRUS; MIDDLE OCCIPITAL GYRUS; MIDDLE TEMPORAL GYRUS; MILD COGNITIVE IMPAIRMENT; NERVE CELL; NERVE DEGENERATION; PARIETAL GYRUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; CLASSIFICATION; COGNITION DISORDERS; COMPLICATION; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84952889115     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv229     Document Type: Article

References (63)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011; 7: 270-9.
2. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004; 61: 378-84.
3. Braskie MN, Thompson PM. Understanding cognitive deficits in Alzheimers disease based on neuroimaging findings. Trends Cogn Sci 2013; 17: 510-16.
4. Brinkmann BH, Jones DT, Stead M, Kazemi N, OBrien TJ, So EL, et al. Statistical parametric mapping demonstrates asymmetric uptake with Tc-99m ECD and Tc-99m HMPAO SPECT in normal brain. J Cereb Blood Flow Metab 2012; 32: 190-8.
5. Casanova R, Srikanth R, Baer A, Laurienti PJ, Burdette JH, Hayasaka S, et al. Biological parametric mapping: A statistical toolbox for multimodality brain image analysis. Neuroimage 2007; 34: 137-43.
6. Catafau AM, Lomena FJ, Pavia J, Parellada E, Bernardo M, Setoain J, et al. Regional cerebral blood flow pattern in normal young and aged volunteers: a 99mTc-HMPAO SPET study. Eur J Nucl Med 1996; 23: 1329-37.
7. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, et al.. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 2009; 29: 14770-8.
8. Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011; 134(Pt 6): 1635-46.
9. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimers disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
10. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501-8.
11. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al.. Two-year follow-up of amyloid deposition in patients with Alzheimers disease. Brain 2006; 129(Pt 11): 2856-66.
12. Forster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Forstl H, et al. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimers disease. Eur J Nucl Med Mol Imaging 2012; 39: 1927-36.
13. Frings L, Spehl TS, Weber WA, Hull M, Meyer PT. Amyloid-beta load predicts medial temporal lobe dysfunction in Alzheimer dementia. J Nucl Med 2013; 54: 1909-14.
14. Furst AJ, Lal RA. Amyloid-beta and glucose metabolism in Alzheimers disease. J Alzheimers Dis 2011; 26 (Suppl 3): 105-16.
15. Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, et al. Cognition, glucose metabolism and amyloid burden in Alzheimers disease. Neurobiol Aging 2012; 33: 215-25.
16. Gefen T, Gasho K, Rademaker A, Lalehzari M, Weintraub S, Rogalski E, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain 2012; 135(Pt 5): 1554-65.
17. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55: 335-46.
18. Hatashita S, Yamasaki H. Diagnosed mild cognitive impairment due to Alzheimers disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One 2013; 8: e66877.
19. Hedden T, Schultz AP, Rieckmann A, Mormino EC, Johnson KA, Sperling RA, et al. Multiple brain markers are linked to age-related variation in cognition. Cereb Cortex 2014. Advance Access published on October 14, 2014, doi: 10.1093/cercor/bhu238.
20. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol 2010; 9: 119-28.
21. Jack CRJ, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013a; 12: 207-16.
22. Jack CRJ, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain 2008; 131(Pt 3): 665-80.
23. Jack CRJ, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain 2009; 132(Pt 5): 1355-65.
24. Jack CRJ, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, et al.. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013b; 81: 1732-40.
25. Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012; 32: 18227-33.
26. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-9.
27. Jagust WJ, Mormino EC. Lifespan brain activity, beta-amyloid, and Alzheimers disease. Trends Cogn Sci 2011; 15: 520-6.
28. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimers association. J Nucl Med 2013; 54: 476-90.
29. Josephs KA, Duffy JR, Strand EA, Machulda MM, Senjem ML, Lowe VJ, et al. APOE epsilon4 influences beta-amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimers Dement 2014; 10: 630-6.
30. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Langstrom B, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimers disease. Neurobiol Aging 2012; 33: 198.e1-14.
31. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
32. Kurth F, Gaser C, Luders E. A 12-step user guide for analyzing voxelwise gray matter asymmetries in statistical parametric mapping (SPM). Nat Protoc 2015; 10: 293-304.
33. La Joie R, Perrotin A, Barre L, Hommet C, Mezenge F, Ibazizene M, et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimers disease dementia. J Neurosci 2012; 32: 16265-73.
34. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72: 578-86.
35. Lowe VJ, Weigand SD, Senjem ML, Vemuri P, Jordan L, Kantarci K, et al.. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 2014; 82: 1959-67.
36. Madhavan A, Whitwell JL, Weigand SD, Duffy JR, Strand EA, Machulda MM, et al. FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimers type. PLoS One 2013; 8: e62471.
37. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJ, Kawas CH, et al. The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging- Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011; 7: 263-9.
38. Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimers and frontotemporal pathology in primary progressive aphasia. Brain 2014; 137(Pt 4): 1176-92.
39. Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med 2011; 52: 393-400.
40. Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S, Rabinovici GD, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009; 73: 1571-8.
41. Mitsis EM, Riggio S, Kostakoglu L, Dickstein DL, Machac J, Delman B, et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry 2014; 4: e441.
42. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimers Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimers disease. Neurology 1989; 39: 1159-65.
43. Mosconi L, Rinne JO, Tsui WH, Murray J, Li Y, Glodzik L, et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimers parents. Neurobiol Aging 2013; 34: 22-34.
44. Ossenkoppele R, Schonhaut DR, Baker SL, ONeil JP, Janabi M, Ghosh PM, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol 2015; 77: 338-42.
45. Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, et al. Amyloid burden and metabolic function in early-onset al.zheimers disease: parietal lobe involvement. Brain 2012; 135(Pt 7): 2115-25.
46. Perlmutter JS, Powers WJ, Herscovitch P, Fox PT, Raichle ME. Regional asymmetries of cerebral blood flow, blood volume, and oxygen utilization and extraction in normal subjects. J Cereb Blood Flow Metab 1987; 7: 64-7.
47. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64: 388-401.
48. Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimers disease with Pittsburgh Compound B. J Neurosci Methods 2008; 172: 277-82.
49. Rapoport SI, Horwitz B, Grady CL, Haxby JV, DeCarli C, Schapiro MB. Abnormal brain glucose metabolism in Alzheimers disease, as measured by position emission tomography. Adv Exp Med Biol 1991; 291: 231-48.
50. Rogalski E, Cobia D, Martersteck A, Rademaker A, Wieneke C, Weintraub S, et al. Asymmetry of cortical decline in subtypes of primary progressive aphasia. Neurology 2014; 83: 1184-91.
51. Shattuck DW, Mirza M, Adisetiyo V, Hojatkashani C, Salamon G, Narr KL, et al.. Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage 2008; 39: 1064-80.
52. Solbach C, Uebele M, Reischl G, Machulla HJ. Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimers Disease with PET. Appl Radiat Isot 2005; 62: 591-95.
53. Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging, 2013; 34: 822-31.
54. Tauber C, Beaufils E, Hommet C, Ribeiro MJ, Vercouillie J, Vierron E, et al. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimers disease patients. J Alzheimers Dis 2013; 36: 311-20.
55. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800.
56. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimers disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in conitively normal older individuals. J Neurosci 2013a; 33: 5553-63.
57. Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ. The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement 2013b; 9: 687-98.e1.
58. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013c; 70: 1512-19.
59. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 2002; 22: 1440-52.
60. Yaqub M, Tolboom N, Boellaard R, van Berckel BN, van Tilburg EW, Luurtsema G, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage 2008; 42: 76-86.
61. Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimers disease. Eur J Nucl Med Mol Imaging 2011; 38: 343-51.
62. Zetterberg H, Blennow K. Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimers disease. Alzheimers Dement 2013; 9: 459-62.
63. Zhou Y, Yu F, Duong TQ. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimers disease patients. J Magn Reson Imaging 2015; 41: 102-9.